Lu et al., 2021 - Google Patents
MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancerLu et al., 2021
View PDF- Document ID
- 14639446168361443703
- Author
- Lu N
- Liu J
- Ji C
- Wang Y
- Wu Z
- Yuan S
- Xing Y
- Diao F
- Publication year
- Publication venue
- Bioengineered
External Links
Snippet
ABSTRACT Uterus Corpus Endometrial cancer (UCEC) is the sixth most common malignant tumor worldwide. In this research, we identified diagnostic and prognostic biomarkers to reflect patients' immune microenvironment and prognostic. Various data of UCEC patients …
- 229920001239 microRNA 0 title abstract description 110
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/22—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or SNP [Single-Nucleotide Polymorphism] discovery or sequence alignment
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer | |
Inamoto et al. | A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder | |
Yang et al. | Identification of hub genes and outcome in colon cancer based on bioinformatics analysis | |
Liu et al. | Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma | |
Lu et al. | MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer | |
Gong et al. | The prognostic signature and potential target genes of six long non-coding RNA in laryngeal squamous cell carcinoma | |
Zhong et al. | Identification of novel mRNA-miRNA-lncRNA competing endogenous RNA network associated with prognosis of breast cancer | |
Tang et al. | Identification of miRNA‐Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer | |
Lin et al. | Four-miRNA signature as a prognostic tool for lung adenocarcinoma | |
Chen et al. | Identification of differentially expressed miRNAs in early-stage cervical cancer with lymph node metastasis across The Cancer Genome Atlas datasets | |
Jia et al. | Exploring the molecular pathogenesis and biomarkers of high risk oral premalignant lesions on the basis of long noncoding RNA expression profiling by serial analysis of gene expression | |
Wu et al. | The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma | |
Li et al. | Prognostic value of the tumor‐specific ceRNA network in epithelial ovarian cancer | |
Yin et al. | Identification of a genome instability-associated LncRNA signature for prognosis prediction in colon cancer | |
Zhou et al. | The landscape of the tumor microenvironment in skin cutaneous melanoma reveals a prognostic and immunotherapeutically relevant gene signature | |
Li et al. | Integrated miRNA‐mRNA expression profiles revealing key molecules in ovarian cancer based on bioinformatics analysis | |
Zhu et al. | Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non‐Small‐Cell Lung Cancer | |
Zhan et al. | Panel of seven long noncoding RNA as a candidate prognostic biomarker for ovarian cancer | |
Liu et al. | An inflammation‐related nine‐gene signature to improve prognosis prediction of lung adenocarcinoma | |
Liao et al. | m6A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia | |
Zhang et al. | Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair‐associated signature | |
Wang et al. | Extracellular matrix-associated pathways promote the progression of gastric cancer by impacting the dendritic cell axis | |
Liu et al. | Pan-cancer analysis predicts FOXS1 as a key target in prognosis and tumor immunotherapy | |
Hu et al. | Prognostic Value of DNA Methylation‐Driven Genes in Clear Cell Renal Cell Carcinoma: A Study Based on Methylation and Transcriptome Analyses | |
Li et al. | A novel long non-coding RNA-based prognostic signature for renal cell carcinoma patients with stage IV and histological grade G4 |